Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 559 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Advanced Breast Cancer (Female) Clear all
Completed Phase 1 Interventional

Study of Continuous OSI-906 Dosing

NCT00514007
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-906
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268
View directory record Official record
Conditions
Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696
View directory record Official record
Conditions
Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer
Interventions
E-602, Cemiplimab
Biological
Lead sponsor
Palleon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Results available

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

NCT04672460
View directory record Official record
Conditions
Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer, Prostate Cancer, NSCLC, Pancreatic Cancer, Colorectal Cancer
Interventions
TALZENNA capsule, Talazoparib soft gel capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
23
States / cities
Encinitas, California • Los Angeles, California • San Marcos, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

NCT01300533
View directory record Official record
Conditions
Metastatic Cancer, Cancer, Solid Tumors
Interventions
BIND-014
Drug
Lead sponsor
BIND Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment

NCT00087958
View directory record Official record
Conditions
Breast Cancer
Interventions
XRP9881
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2009 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 3 Interventional

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

NCT00241449
View directory record Official record
Conditions
Breast Cancer, Metastasis
Interventions
Fulvestrant, Tamoxifen
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
24
States / cities
Little Rock, Arkansas • Fountain Valley, California • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00003548
View directory record Official record
Conditions
Cancer
Interventions
aminocamptothecin colloidal dispersion
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 9, 2026, 5:24 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264
View directory record Official record
Conditions
Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions
BG-68501, Fulvestrant, BGB-43395
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

NCT03761914
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
Interventions
galinpepimut-S, pembrolizumab, Montanide, GM-CSF
Biological · Other
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
12
States / cities
Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 9, 2026, 5:24 PM EDT
Terminated No phase listed Observational

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

NCT02900248
View directory record Official record
Conditions
Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions
Provider determined
Other
Lead sponsor
CureOne
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 3 Interventional

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

NCT00232661
View directory record Official record
Conditions
Breast Cancer
Interventions
ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older · Female only
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
13
States / cities
Santa Rosa, California • New Britain, Connecticut • Torrington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 9, 2026, 5:24 PM EDT
Not listed Phase 1 Interventional

Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00090727
View directory record Official record
Conditions
Solid Malignancies, Non-Hodgkin's Lymphoma
Interventions
AQ4N
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2006 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

NCT00333502
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Duarte, California • Farmington, New Mexico
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

NCT02049957
View directory record Official record
Conditions
Breast Cancer
Interventions
Sapanisertib, Fulvestrant, Exemestane
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

NCT02463032
View directory record Official record
Conditions
ER+ and AR+ Breast Cancer
Interventions
GTx-024
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Boston, Massachusetts • Billings, Montana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 9, 2026, 5:24 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years to 130 Years · Female only
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
14
States / cities
Casa Grande, Arizona • Fountain Valley, California • New Britain, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 9, 2026, 5:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371
View directory record Official record
Conditions
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Interventions
BT5528, Nivolumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Encinitas, California • Orange, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

NCT04319757
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer
Interventions
ACE1702, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Acepodia Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

NCT02014337
View directory record Official record
Conditions
Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms
Interventions
Mifepristone and Eribulin in combination
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

NCT02983045
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Interventions
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 9, 2026, 5:24 PM EDT
Terminated Phase 1 Interventional

A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

NCT03429101
View directory record Official record
Conditions
Breast Cancer
Interventions
Poziotinib, T-DM1
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Anaheim, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 9, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

NCT01068483
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Ovarian Cancer, Endometrium Cancer
Interventions
BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 9, 2026, 5:24 PM EDT
Withdrawn Phase 1 Interventional

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

NCT01386502
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer
Interventions
p53: 264-272 peptide, CT-011
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 9, 2026, 5:24 PM EDT